Maxim Group analyst Naz Rahman maintained a Buy rating on Virpax Pharmaceuticals (VRPX – Research Report) yesterday and set a price target of $4.00. The company’s shares opened today at $0.77.
Rahman covers the Healthcare sector, focusing on stocks such as Clene, scPharmaceuticals, and Virpax Pharmaceuticals. According to TipRanks, Rahman has an average return of -4.3% and a 33.04% success rate on recommended stocks.
Currently, the analyst consensus on Virpax Pharmaceuticals is a Moderate Buy with an average price target of $4.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.35 and a one-year low of $0.61. Currently, Virpax Pharmaceuticals has an average volume of 41.45K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
Read More on VRPX:
